Sutezolid is primarily investigated for its potential in treating tuberculosis (TB), particularly drug-resistant strains. It works by inhibiting bacterial protein synthesis, making it effective against Mycobacterium tuberculosis. Its application is significant in addressing multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), where conventional treatments fail. Sutezolid is being studied in combination therapies to enhance efficacy and reduce treatment duration. Its oral bioavailability and favorable safety profile make it a promising candidate for improving TB management, especially in resource-limited settings. Ongoing clinical trials aim to establish its role in global TB control strategies.